{"filings":[{"id":536116,"accession_number":"0001635088-26-000060","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2026-05-20T11:14:10+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant reports Q4 GAAP EPS $0.28 on Moderna settlement; IMVT-1402 D2T RA ACR20 72.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP income from continuing ops $355.7M ($0.28 diluted EPS) vs loss of $252.4M ($0.29 loss) YoY; includes $770M gain on Moderna settlement.","Non-GAAP loss from continuing ops $222.7M in Q4 vs $154.4M loss YoY; FY loss $747.7M vs $623.9M.","IMVT-1402 in D2T RA: Week 16 ACR20 72.7%, ACR50 54.5%, ACR70 35.8% in open-label period; 170 patients enrolled.","Brepocitinib NDA for DM accepted with Priority Review; launch by end Sep 2026. Breakthrough Therapy for cutaneous sarcoidosis.","Moderna settlement: $2.25B global; $950M due July 2026; additional $1.3B contingent on appeal resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94258,"accession_number":"0001140361-26-012885","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Batoclimab TED Phase 3 misses endpoint; Roivant starts brepocitinib LPP trial; $4.3B cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities as of Mar 31, 2026: ~$4.3B.","Repurchased 3,956,362 common shares for ~$109.7M in Q4 fiscal 2026.","Immunovant's two Phase 3 studies of batoclimab in TED failed to meet primary endpoint of ≥2mm proptosis responder rate at Week 24.","Priovant began Phase 2b/3 trial of brepocitinib in lichen planopilaris; first subjects enrolled Mar 2026.","Brepocitinib NDA for dermatomyositis granted Priority Review; PDUFA target in Q3 calendar 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106476,"accession_number":"0001140361-26-010656","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K/A","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves all US and international patent infringement litigation between Genevant/Arbutus and Moderna over LNP technology in COVID-19 and other mRNA vaccines.","Moderna receives broad license to Genevant/Arbutus patent rights for defined Moderna Licensed Products, including SPIKEVAX, mNEXSPIKE, mRESVIA, and certain other mRNA vaccines.","Moderna will make a noncontingent lump-sum payment (amount redacted) and a contingent payment tied to the outcome of Moderna's appeal on the §1498 government-contractor defense.","Parties stipulate to dismissal of US and ex-US litigation with prejudice; Moderna retains right to appeal only on the §1498 Disputed Matter.","Moderna agrees not to challenge validity/enforceability of specified patents owned by Genevant/Arbutus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106479,"accession_number":"0001140361-26-007548","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Moderna to pay $950M non-contingent by July 8, 2026; additional $1.3B if Federal Circuit affirms rejection of Section 1498 defense.","Settlement includes judgment of no invalidity on four Genevant/Arbutus patents and a global non-exclusive license to LNP tech for infectious disease mRNA vaccines.","Roivant board authorizes $1B share repurchase program (includes prior $500M authorization), no expiration date.","Genevant/Arbutus continues litigation against Pfizer/BioNTech; Comirnaty sales represent ~2/3 of global COVID mRNA vaccine sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106478,"accession_number":"0001140361-26-007447","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts brepocitinib NDA for dermatomyositis, grants Priority Review; PDUFA Q3 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA and granted Priority Review for brepocitinib in dermatomyositis; PDUFA target action date in Q3 2026.","Launch expected at end of September 2026 if approved; supported by positive Phase 3 VALOR trial (N=241).","VALOR was first positive 52-week placebo-controlled study in dermatomyositis; brepocitinib 30mg met primary endpoint and all nine key secondary endpoints.","If approved, brepocitinib would be first targeted therapy for dermatomyositis; safety profile similar to approved JAK/TYK2 inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106477,"accession_number":"0001635088-26-000009","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant reports positive Phase 2 brepocitinib data in CS; Q3 loss $313.7M vs $208.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 BEACON study: brepocitinib 45mg achieved 22.3-point CSAMI-A improvement vs 0.7 placebo (Δ21.6, p<0.0001).","NDA submitted to FDA for brepocitinib in dermatomyositis; Phase 3 CS study planned for 2026.","Q3 loss from continuing ops $313.7M ($0.38/share) vs $208.9M ($0.22); revenue fell to $2M from $9M.","Cash and marketable securities of $4.5B as of Dec 31, 2025; R&D expenses rose to $165.4M.","Immunovant's IMVT-1402 D2T RA trial fully enrolled; Genevant jury trial set for Mar 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":5740000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122824,"accession_number":"0001140361-25-045204","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roivant accelerates key pipeline timelines; Immunovant raises $550M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brepocitinib NDA filing in dermatomyositis expected early 2026; commercial launch early 2027.","Phase 3 brepocitinib trial in non-infectious uveitis fully enrolled; topline data now H2 2026.","Brepocitinib proof-of-concept in cutaneous sarcoidosis fully enrolled; topline data now H1 2026.","IMVT-1402 potentially registrational trial in D2T RA topline data now expected CY 2026.","Immunovant financing led by Roivant generated ~$550M gross proceeds, extending cash runway to IMVT-1402 launch in GD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122823,"accession_number":"0001140361-25-041269","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q2 net loss $113.5M; brepocitinib Phase 3 DM trial succeeds on all endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Brepocitinib 30 mg met primary and all nine key secondary endpoints in Phase 3 VALOR DM study; NDA filing planned H1 2026.","Net loss attributable to Roivant $113.5M ($0.17/sh) vs $230.2M ($0.31) a year ago; revenue $1.6M.","Cash and marketable securities $4.4B as of Sept 30, 2025; R&D spend $164.6M (up 15% YoY).","Immunovant batoclimab TED: first Phase 3 readout by end-2025, but both studies to release concurrently in H1 2026 due to competitive dynamics.","Favorable Markman ruling in Pfizer/BioNTech LNP litigation; Moderna jury trial scheduled March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":3741000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139520,"accession_number":"0001140361-25-035190","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Roivant/Priovant: Phase 3 VALOR brepocitinib meets primary endpoint in dermatomyositis; NDA filing 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brepocitinib 30 mg achieved week-52 mean TIS 46.5 vs placebo 31.2 (p=0.0006); all 9 key secondary endpoints met.","62% of brepocitinib patients on background steroids achieved steroid dose ≤2.5 mg/day vs 34% placebo; 42% off steroids vs 23%.","Safety profile consistent with prior brepocitinib trials; no increase in AESIs in active arm vs placebo.","NDA submission for brepocitinib in dermatomyositis planned for calendar first half 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139519,"accession_number":"0001140361-25-034711","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Roivant Sciences shareholders re-elect three directors, ratify auditor, approve say-on-pay at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Matthew Gline, Keith Manchester, Melissa Epperly re-elected as Class I directors; each received >72% of votes cast excluding broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2026: 628M for, 479K against, 125K abstain.","Non-binding say-on-pay approved: 316.7M for, 203.2M against, 64.6M abstain, 44.2M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139518,"accession_number":"0001140361-25-033767","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Roivant reports ~80% durability and ~50% ATD-free remission in Graves' disease data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Of 21 patients in 6-month off-treatment follow-up, ~80% (17/21) maintained normal thyroid function.","~50% of responders (8/17) achieved anti-thyroid drug-free remission after 6 months off batoclimab.","Two registrational trials for IMVT-1402 in Graves' disease are enrolling; topline data expected 2027.","Safety consistent with prior batoclimab studies; first potential disease-modifying therapy for uncontrolled GD.","Roivant and Immunovant to host investor call Sept 3, 2025 at 4:30 p.m. EDT to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139517,"accession_number":"0001140361-25-029998","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q1 loss widens to $0.33/share; completes $1.5B buyback, initiates new $500M program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP loss from continuing ops $273.9M ($0.33/share) vs income $31.6M ($0.01) YoY; revenue $2.2M down from $8.0M.","Non-GAAP loss from continuing ops $170.1M vs $107.1M YoY; R&D spend up $32.4M to $152.9M.","Completed $1.5B share repurchase program; board approved new $500M buyback in June 2025.","Cash, equivalents, restricted cash and marketable securities $4.5B; shares outstanding reduced >15% from Mar 2024.","Brepocitinib VALOR DM Phase 3 topline data H2 2025 (LPLV July); IMVT-1402 registrational trials started in GD, SjD June."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":2170000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157088,"accession_number":"0001140361-25-023553","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant Sciences authorizes $500M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $500M buyback authorization effective June 24, 2025, in addition to prior $1.5B program now exhausted.","Program has no expiration date; funded from available cash and cash equivalents.","Repurchases may be executed via open market, tender offers, or 10b5-1 trading plans.","Timing and size depend on market price, business conditions, and other investment opportunities.","The program may be suspended or discontinued at any time at the company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157087,"accession_number":"0001140361-25-020713","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q4 net loss widens to $206.5M; brepocitinib DM readout on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Roivant of $206.5M ($0.29 loss per share) for Q4 FY2025, vs $151.1M loss ($0.19) a year ago.","Revenue of $7.6M, down 16% YoY; R&D expenses rose 35% to $145.2M.","Consolidated cash, equivalents, restricted cash and marketable securities of $4.9B at March 31, 2025.","Repurchased $1.3B of shares, reducing outstanding shares by 14% from March 31, 2024.","Brepocitinib Phase 3 in dermatomyositis fully enrolled; topline data expected H2 2025; NIU Phase 3 enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":29053000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157086,"accession_number":"0001140361-25-014642","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunovant CEO Pete Salzmann retires; Eric Venker appointed; IMVT-1402 adds SjD and CLE indications","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pete Salzmann retired as Immunovant CEO and Director; Eric Venker (Roivant President & COO) appointed CEO; Tiago Girao named CFO.","IND cleared for IMVT-1402 in Sjögren’s Disease; registrational study expected summer 2025.","Proof-of-concept study initiated for IMVT-1402 in Cutaneous Lupus Erythematosus (CLE).","Roivant to lead Immunovant investor relations; cash runway supports through Graves' Disease readout in 2027.","Robert Susman and Jacob Bauer join Immunovant Board; George Migausky steps down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175461,"accession_number":"0001140361-25-009696","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Roivant enters consulting agreement with former CAO Rakhi Kumar for 18-month transition services","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rakhi Kumar stepped down as Chief Accounting Officer effective Feb 20, 2025; consulting agreement dated March 16, 2025.","She will provide advisory and transition services as reasonably requested by Roivant Sciences Inc.","During the 18-month term, she continues vesting in outstanding equity incentive awards.","Remaining unvested equity awards will fully vest at term end if she complies with obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175460,"accession_number":"0001140361-25-009362","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Roivant and Immunovant announce positive Phase 3 batoclimab MG results and initial Phase 2b CIDP results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 MG study met primary endpoint with 5.6-point MG-ADL improvement at 12 weeks in high-dose batoclimab arm.","Initial CIDP Phase 2b Period 1 data showed 1.8-point aINCAT improvement and 84% responder rate in patients with ≥70% IgG reduction.","Immunovant plans to initiate registrational studies for IMVT-1402 in MG and CIDP.","Deeper IgG reductions correlated with better clinical outcomes across both studies.","Conference call held on March 19, 2025 at 8:00 a.m. ET to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175459,"accession_number":"0001140361-25-005445","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Roivant Sciences appoints Jennifer Humes as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rakhi Kumar stepped down as Principal Accounting Officer and Chief Accounting Officer effective February 20, 2025.","Jennifer Humes appointed as successor; previously Managing Director at JPMorgan Chase leading 80+ controllers.","Humes receives annual base salary of $380,000, sign-on bonus of $261,500, and target annual cash bonus of $190,000.","Equity grants: RSUs valued ~$1.2M and options valued ~$800,000 (Black-Scholes), vesting over multi-year schedules.","No family relationships or related-person transactions involving Humes and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175458,"accession_number":"0001140361-25-003639","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q3 loss $208.9M; cash $5.2B; launches brepocitinib Ph2 in sarcoidosis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.0M (-42% YoY); loss from continuing ops $208.9M vs. $5.1B income in prior year (Telavant gain).","Cash and marketable securities $5.2B at Dec 31; plus $75M VTAMA milestone and $113M from Immunovant private placement.","New brepocitinib Phase 2 in cutaneous sarcoidosis; topline data expected H2 2026.","Batoclimab pivotal trial results in MG and CIDP expected by March 31, 2025; IMVT-1402 pivotal trials initiated in GD and D2T RA.","LNP litigation vs. Moderna: summary judgment Q2/Q3 2025, jury trial Sept 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":21483000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192410,"accession_number":"0001140361-24-048238","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roivant: Phase 2 namilumab study fails in sarcoidosis; development discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Namilumab failed to meet the primary endpoint (proportion of subjects with a Rescue Event) in chronic active pulmonary sarcoidosis.","Secondary endpoints (FVC, corticosteroid tapering, King's Sarcoidosis Questionnaire) also showed no treatment benefit.","Safety profile remained consistent with prior studies; no new safety signals emerged.","Kinevant will discontinue further development of namilumab for sarcoidosis and plans to publish study results.","Roivant CEO Matt Gline acknowledged the failure but highlighted other program successes and continued clinical risk-taking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192409,"accession_number":"0001140361-24-046015","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q2 loss $236.8M; Dermavant deal closed; cash $5.4B; brepocitinib NIU data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 loss from continuing ops $236.8M ($0.25 EPS); R&D $143.1M; G&A $202.9M up $114.3M YoY on retention awards.","Dermavant transaction closed Oct 28: Roivant received $184M cash; Organon assumed $336M debt; $75M milestone pending VTAMA FDA approval for atopic dermatitis.","Consolidated cash, cash equivalents and marketable securities ~$5.4B at Sep 30, 2024.","Share repurchases $106M in Q2; cumulative $754M (incl. Sumitomo stake buyback).","Pipeline: brepocitinib Phase 2 NIU 52-wk data shows sustained efficacy; batoclimab GD 76% response; mosliciguat PVR reduction ~38%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":12465000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192408,"accession_number":"0001140361-24-044434","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Roivant subsidiary Dermavant acquired by Organon; merger closed Oct 28, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Organon completed acquisition of Dermavant from Roivant on October 28, 2024, expanding dermatology portfolio.","VTAMA (tapinarof) cream 1% is FDA-approved for plaque psoriasis; sNDA for atopic dermatitis under review with PDUFA in Q4 2024.","Dermavant's credit agreement terminated upon closing; all amounts outstanding repaid.","Roivant President cites win-win outcome; expects to share meaningfully in VTAMA's success via collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208878,"accession_number":"0001140361-24-041663","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Roivant sells Dermavant to Organon for up to $1.2B in cash plus royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to ~$1.2B: $175M at closing, $75M milestone on FDA approval for atopic dermatitis, up to $950M in net sales milestones.","Tiered royalties: low-to-mid single-digit % on net sales up to $1B, 30% on net sales above $1B; all paid pro rata to Dermavant equity holders.","Roivant owns ~87% of Dermavant; merger expected to close Q4 2024, subject to HSR and antitrust conditions.","Organon will assume Dermavant's existing revenue interest purchase and funding agreements at closing.","Merger approved by Dermavant and Roivant boards and by shareholders holding at least 75% voting rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208877,"accession_number":"0001140361-24-041344","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roivant's Dermavant to be acquired by Organon for $1.2B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Organon (OGN) will acquire Dermavant, a Roivant (ROIV) subsidiary, for $1.2B in cash and milestone payments.","Deal includes VTAMA cream (tapinarof) 1%, approved for plaque psoriasis in adults (May 2022).","sNDA for atopic dermatitis under FDA review; PDUFA decision expected Q4 2024.","VTAMA is a once-daily steroid-free topical with no safety label warnings or duration/BSA restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208876,"accession_number":"0001140361-24-041188","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Roivant shareholders re-elect three Class III directors, ratify EY auditor, approve say-on-pay annually","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Ilan Oren, James Momtazee, Dr. Mayukh Sukhatme re-elected with 68%-92% of votes cast.","Ernst & Young ratified as independent auditor for FY2025; 679M for, 0.8M against.","Non-binding advisory vote on executive compensation approved: 540M for, 64.5M against.","Advisory vote frequency set to every one year (600.7M votes); company will hold annual say-on-pay votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208875,"accession_number":"0001140361-24-040650","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roivant unveils mosliciguat, inhaled sGC activator for PH-ILD; Phase 1b shows PVR reduction up to 38%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b ATMOS in 38 PH patients: single dose of mosliciguat produced mean-max PVR reduction up to ~38%, exceeding ≥20% threshold.","Mosliciguat is potential first-in-class, inhaled once-daily sGC activator with targeted lung delivery via dry powder inhaler.","Global Phase 2 PHocus study in ~120 PH-ILD patients imminent; PH-ILD prevalence ~200,000 in US/Europe with few treatments.","Roivant in-licensed from Bayer for ~$14M upfront, up to $280M milestones + tiered high-single digit royalties.","Favorable safety in 170 participants; 40-hour half-life enables once-daily dosing; differentiated from existing therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208874,"accession_number":"0001140361-24-040507","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roivant/Immunovant: Phase 2a batoclimab 76% response in GD; pivotal IMVT-1402 trial by year end","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["High-dose batoclimab (680mg SC weekly) achieved 76% response rate and 56% ATD-free response in uncontrolled GD at week 12.","Mean IgG reduction of 77% correlated with clinical outcomes; ≥70% IgG reduction yielded 60% ATD-free response vs 23%.","FDA cleared IND for IMVT-1402; pivotal trial in Graves' Disease expected to initiate by December 31, 2024.","Real-world data shows 25-30% of GD patients per year are uncontrolled on ATDs, representing a large commercial opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208873,"accession_number":"0001140361-24-036281","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q1 net income $57.5M, cash $5.7B; pipeline advances in MG, DM, NIU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $57.5M vs net loss of $327.8M YoY; diluted EPS $0.12 vs ($0.38).","Total revenue $55.1M, product revenue $18.4M from VTAMA; license/milestone $36.8M.","Cash, cash equivalents and restricted cash $5.7B at June 30, 2024, reflecting $648M share repurchase.","Immunovant completed enrollment in batoclimab pivotal MG trial; brepocitinib Phase 3 VALOR in DM completed enrollment.","Priovant to initiate Phase 3 for brepocitinib in NIU; VTAMA PDUFA action expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":55132000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226680,"accession_number":"0001140361-24-027994","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Roivant subsidiary Dermavant renegotiates debt, reduces potential payments by over $300M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Dermavant caps RIPSA royalties at $6M/yr for FY2025-2027, reducing near-term cash outflow.","Credit Agreement maturity extended to May 2028; interest rate increased to 12.25% from 10%.","NovaQuest fixed quarterly payments of $176.3M eliminated; up to $141M in commercial milestones also eliminated.","Roivant commits $195M in convertible preferred equity at 1.5x liquidation preference; DSL issues ~13.2% common shares to lenders.","Post-closing, Roivant owns ~87% of DSL common/preferred (~82% fully diluted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226679,"accession_number":"0001140361-24-027986","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant reports FY2024 GAAP income from continuing ops $4.2B on $5.3B Telavant gain; Q4 loss $182.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue from VTAMA (psoriasis) $75.1M for FY2024; over 385K prescriptions since launch.","Cash, cash equivalents and restricted cash $6.6B at March 31, 2024; after $648.4M share repurchase from Sumitomo, pro forma $5.9B.","Non-GAAP loss from continuing operations $799.9M for FY2024 vs $924.3M prior year.","Dermavant debt renegotiated reducing potential payments by over $300M; $225M reduction expected over next three fiscal years.","Pipeline: Priovant to initiate pivotal brepocitinib trial in NIU in H2 2024; Immunovant expects 4-5 registrational studies by March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":5.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":124795000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226678,"accession_number":"0001140361-24-017141","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant reports positive Phase 2 NIU data; authorizes $1.5B buyback, repurchases Sumitomo's 9% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 NEPTUNE: brepocitinib 45mg arm had 29% Treatment Failure at week 24 (vs 44% for 15mg), best observed in NIU studies.","All secondary endpoints positive; 43% of patients with baseline macular edema achieved resolution by week 24 on 45mg.","Board authorized up to $1.5B share repurchase; $648.4M to buy Sumitomo's 71.3M shares at $9.10, reducing shares outstanding by ~9%.","Phase 3 program in NIU to start H2 2024; Phase 3 dermatomyositis study fully enrolled Q3 2024, data expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245645,"accession_number":"0001140361-24-007259","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant posts $5.1B net income on $7.1B Telavant sale to Roche; cash at $6.7B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $5.1B ($6.37 basic EPS) vs loss of $384.9M a year ago, driven by $5.3B gain on Telavant sale.","Net cash proceeds from Telavant sale ~$5.2B; consolidated cash, cash equivalents and restricted cash $6.7B at Dec 31, 2023.","VTAMA net product revenue $20.7M for Q3; over 300k prescriptions written by ~14k prescribers since launch.","Batoclimab Phase 2 Graves' disease trial shows >50% response rate in initial cohort; additional data ongoing.","Non-GAAP net loss $174.9M; R&D expenses $123.7M; SG&A $197.3M; RVT-2001 development discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":5.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":95865000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263116,"accession_number":"0001140361-23-058688","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Roivant reports positive Phase 2 batoclimab data in Graves' disease; response >50%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial cohort in Phase 2 trial of batoclimab in Graves' disease showed response rates meaningfully exceeding 50%.","Batoclimab 680 mg SC achieved up to 87% IgG reduction, mean 81% at 12 weeks; 340 mg showed lower reductions.","Across clinical parameters, numerically higher responses with 680 mg vs 340 mg, including ATD dose reduction and discontinuation.","Batoclimab generally well tolerated with no new safety signals observed in the initial data set.","Immunovant plans to focus future Graves' development on IMVT-1402, with details expected later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263110,"accession_number":"0001140361-23-058659","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K/A","filed_at":"2023-12-20T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Roivant files pro forma financials for $7.1B Telavant sale to Roche; gain of $5.3B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Roivant sold its 75% stake in Telavant to Roche for ~$7.1B cash plus $150M milestone for Phase 3 trial initiation.","Pro forma cash and cash equivalents at Sep 30, 2023: $6.6B, up from $1.4B historical.","Pro forma net income attributable to Roivant for FY Mar 2023: $4.3B vs historical net loss of $1.1B.","Pro forma net loss for H1 Sep 2023: $552M vs historical loss of $596M; reduction from eliminated Telavant R&D.","Transaction accounted for as sale of nonfinancial assets; $5.3B gain recognized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263115,"accession_number":"0001140361-23-057578","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Roivant closes $7.1B sale of Telavant to Roche; retains 75% ownership prior to closing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total upfront cash consideration of approximately $7.1 billion paid to Telavant equity holders.","Roivant owned 75% of Telavant on an as-converted basis before the transaction closed.","Additional $150 million cash milestone payable upon initiation of a Phase 3 ulcerative colitis trial.","Telavant holds US and Japan rights to TL1A antibody RVT-3101 for IBD and Crohn's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263114,"accession_number":"0001140361-23-054826","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant: IMVT-1402 600 mg Phase 1 data shows best-in-class potential; 74% IgG reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four weekly SC doses of 600 mg IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% reduction.","Serum albumin and LDL-C at Day 29 showed no significant change from baseline (p>0.05), indicating placebo-like safety.","Steady-state IgG reduction expected to reach ~80% with continued weekly dosing, matching batoclimab's timing of 6-8 weeks.","Treatment was well tolerated with only mild or moderate adverse events observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263113,"accession_number":"0001140361-23-054630","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant subsidiary Priovant's Phase 2 lupus study of oral brepocitinib fails primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral brepocitinib did not meet primary endpoint of SRI-4 at Week 52 in moderate-to-severe active lupus.","Highest placebo response rate observed in any significant SLE study prevented differentiation; active arm showed high SRI-4 rates.","Priovant will not progress brepocitinib in SLE but continues in non-infectious uveitis and dermatomyositis.","Topline results for NIU Phase 2 expected Q1 2024; dermatomyositis Phase 3 topline in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263112,"accession_number":"0001140361-23-052718","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant reports Q2 net loss $331M; announces $7.1B Telavant sale to Roche","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $331.1M ($0.40/share) vs $315.9M prior year; revenue $37.1M up from $12.5M.","Sold Telavant to Roche for $7.1B upfront + $150M milestone; Roivant net proceeds ~$5.2B.","VTAMA net product revenue $18.4M in quarter; over 250k prescriptions since launch.","Pro forma cash ~$7.0B after Telavant and Immunovant offerings; R&D spend $132M.","IMVT-1402 Phase 1 data show dose-dependent IgG reduction with no significant albumin/LDL-C changes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":58725000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263111,"accession_number":"0001140361-23-049091","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Roche to acquire Telavant for $7.1B upfront; Roivant owns 75% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Roche pays $7.1B cash at closing plus $150M milestone for rights to RVT-3101 in US and Japan.","Roivant owns 75% of Telavant and will receive the majority of proceeds; Pfizer owns 25%.","RVT-3101 showed 36% clinical remission and 50% endoscopic improvement at week 56 in Phase 2b UC trial.","Roche obtains option to collaborate with Pfizer on a next-generation p40/TL1A bispecific antibody (Phase 1).","Transaction expected to close in Q4 2023 or Q1 2024, subject to HSR and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280334,"accession_number":"0001140361-23-046010","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Roivant Sciences raises ~$200M via registered direct offering of 19.6M shares at $10.21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 19,600,685 common shares at $10.21 each for aggregate gross proceeds of ~$200.1 million.","Net proceeds to be used for investment into subsidiary Immunovant, Inc. and for working capital and general corporate purposes.","Offering made pursuant to prospectus supplement under effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280333,"accession_number":"0001140361-23-045178","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunovant announces positive initial Phase 1 data for IMVT-1402; IgG reduction without albumin or LDL-C changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SC doses of IMVT-1402 achieved peak IgG reductions similar to batoclimab with no decrease in serum albumin or increase in LDL-C.","In 300 mg MAD cohort, mean total IgG reduction from baseline was 63% after 4 weekly doses; no albumin drop or LDL-C rise observed.","All adverse events were mild or moderate; no significant albumin reduction or LDL-C increase at any timepoint (all p>0.05).","Dosing for 600 mg MAD cohort has recently begun; additional MAD data expected in November 2023.","IMVT-1402 delivered as simple 2 mL SC injection at 150 mg/mL; SAD data showed potency similar to or greater than batoclimab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280332,"accession_number":"0001140361-23-044154","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders elect two Class II directors and ratify EY as auditor at 2023 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daniel Gold elected as Class II director with 480,335,783 votes for, 189,651,604 withheld.","Meghan FitzGerald elected as Class II director with 668,955,006 votes for, 1,032,381 withheld.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 709,944,901 for, 65,948 against, 253,423 abstain.","Total shares present at meeting: 710,264,272 out of 768,357,739 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280331,"accession_number":"0001140361-23-043448","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant completes redemption of outstanding warrants; most exercised for shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["20,061,507 public warrants exercised cashless for 5,005,531 common shares; 397 exercised for cash at $11.50.","All private warrants exercised cashless for 2,548,621 common shares.","Redemption price was $0.10 per warrant; warrants delisted from Nasdaq.","Common shares continue trading under ROIV on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280330,"accession_number":"0001140361-23-040270","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant sets warrant redemption FMV at $11.35; cashless exercise yields 0.2495 shares per warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redemption Fair Market Value of $11.35 determined for outstanding public and private warrants.","Warrant holders electing cashless (Make-Whole Exercise) receive ~0.2495 common shares per warrant.","Redemption date: Sept 1, 2023; unexercised warrants void and receive $0.10 per warrant.","Public warrants (ROIVW) to cease trading on Nasdaq at 5:00 PM NY time on redemption date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280329,"accession_number":"0001140361-23-039405","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant reports Q1 net loss of $327.8M, VTAMA revenue $16.7M; cash $1.45B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $327.8M ($0.38/share) vs $353.8M ($0.48) YoY; non-GAAP net loss $211.5M.","Product revenue $16.7M from VTAMA (26% gross-to-net yield); ~200K prescriptions since launch.","Cash, equivalents, restricted cash $1.45B at June 30, down from $1.69B at March 31.","RVT-3101 shows improved efficacy at week 56 in UC Phase 2b; TAHOE Phase 2 in Crohn's initiated.","IMVT-1402 Phase 1 data expected Sep 2023 (SAD) and Oct/Nov 2023 (MAD); batoclimab MG data H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":21624000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280328,"accession_number":"0001140361-23-038093","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Hiroshi Nomura resigns from Roivant board effective Aug 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hiroshi Nomura, Class III director, to resign from board effective August 31, 2023.","Resignation is to focus on other business affairs; no disagreement with company.","No replacement named; board size reduces."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280327,"accession_number":"0001140361-23-037629","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant announces redemption of all outstanding warrants at $0.10 each, effective September 1, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redemption of all outstanding public and private warrants at $0.10 each; redemption date Sept 1, 2023, 5:00 p.m. NY time.","Holders may exercise for cash at $11.50/share or on cashless basis for up to 0.361 common shares per warrant.","Share price condition met as of July 28, 2023 — common shares closed at $10+ for 20 of 30 trading days.","Unexercised warrants after the redemption date will be void and only eligible for $0.10 redemption price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298861,"accession_number":"0001140361-23-031794","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant Q4/FY2023: VTAMA net rev $13.7M, $28.0M FY; RVT-3101 UC data positive; cash $1.7B; FY loss $1.23B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VTAMA net product revenue $13.7M in Q4, $28.0M FY; 170k prescriptions since launch; 76% US commercial lives covered.","RVT-3101 improved efficacy from week 14 to week 56 in Phase 2b UC study; Phase 2 Crohn's initiated, data expected Q4 2024.","VTAMA met primary and all secondary endpoints in Phase 3 ADORING 1/2 for atopic dermatitis in 813 patients including children aged 2+.","Cash and equivalents $1.7B at March 31, 2023; cash runway into H2 2025. GAAP loss from continuing ops $175M Q4 ($0.20/share).","FY2023 GAAP loss from continuing ops $1.23B ($1.58/share); net loss attributable to Roivant $1.01B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298857,"accession_number":"0001140361-23-031820","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K/A","filed_at":"2023-06-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Roivant corrects Immunovant TED Phase 3 data timeline to H1 2025; reports Q4 revenue $27.4M, loss $0.05/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Corrected timeline for Immunovant's Phase 3 TED trials: topline data expected in H1 2025 (previously misstated).","Q4 product revenue from VTAMA $13.7M; fiscal year VTAMA revenue $28.0M; over 170,000 prescriptions since launch.","Cash and equivalents $1.7B as of March 31, 2023; cash runway into H2 2025.","RVT-3101 Phase 2b UC data showed improved efficacy from week 14 to week 56; Phase 2 Crohn's study initiated.","Net loss attributable to Roivant $33.6M ($0.05 per share) for Q4 vs $270.1M loss year ago; loss from continuing ops $175.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298860,"accession_number":"0001140361-23-030856","cik":1635088,"company_name":"Roivant Sciences Ltd.","ticker":"ROIV","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Roivant reports positive chronic data for RVT-3101 in ulcerative colitis, efficacy improved from induction at week 56","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At expected Phase 3 dose, Clinical Remission 36% at week 56 vs 29% at week 14; Endoscopic Improvement 50% vs 36%.","In biomarker-positive patients, Clinical Remission 43% at week 56 (33% at week 14), Endoscopic Improvement 64% (47%).","Favorable safety profile through 56 weeks; 0% neutralizing antibodies at week 56 at Phase 3 dose.","First long-duration data for an anti-TL1A antibody; results support Phase 3 potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21358734049.14554,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-22T23:59:59+00:00|298860"}